Schüchner, Stefan
Andorfer, Peter
Mudrak, Ingrid
Ogris, Egon
Article History
Received: 5 May 2016
Accepted: 18 July 2016
First Online: 17 August 2016
Competing interests
: Egon Ogris serves as a consultant to Millipore Corporation. Monoclonal antibody against PME1 (clone 8A6-F8) is licensed to Biolegend and EMD Millipore, Lamin A/C (clone 3A6-4C11) is licensed to Active Motif, Cell Signaling Technology, Enzo Life Sciences, and Sigma, and PP2A B55α (clone 2G9) is licensed to Abcam, Cell Signaling Technology, EMD Millipore, Enzo Life Sciences, Santa Cruz, and Sigma. Anti-BLUE monoclonal antibodies (clones 2D2-F11 or 6F4-F6) are licensed to Diagenode, Novus, Expedeon and Cell Signaling Technology. The anti-RAINBOW antibody will be available from Diagenode. The royalties paid by these companies were used for performing this work. A patent application related to this research was filed August 22, 2014 (PCT/EP2014/067948). Egon Ogris and Stefan Schüchner receive royalties from the anti-BLUE sales.